Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | BET and FLT3 inhibitor combinations for FLT3-ITD AML

Mark Levis • 27 May 2021
EHA 2021
Acute Myeloid Leukemia Leukemia

Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses using a combination therapy of bromodomain and extraterminal protein (BET) inhibitors and FMS-like tyrosine kinase 3 (FLT3) inhibitors to treat patients with FLT3 internal tandem duplication (FLT3-ITD)-mutated acute myeloid leukemia (AML). Dr Levis discusses how the difficulties of killing leukemic cells in the bone marrow microenvironment led to the development of this combination therapy in vitro. Promising in vitro results support the proposal that this combination therapy may be effective in clinical trials. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Mark Levis

Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3m AML
0:46
Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3m AML
Mark Levis • 12 Jun 2026
The impact of prior induction cycle number on outcomes with gilteritinib in R/R FLT3-mutated AML
0:53
The impact of prior induction cycle number on outcomes with gilteritinib in R/R FLT3-mutated AML
Mark Levis • 12 Jun 2026
Datasets at ASH 2025 that will refine the management of FLT3-mutated AML
1:39
Datasets at ASH 2025 that will refine the management of FLT3-mutated AML
Mark Levis • 5 Dec 2025
Understanding the results of MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD AML
2:03
Understanding the results of MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD AML
Mark Levis • 5 Dec 2025

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals